Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasd...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies....
Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint....
Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year....
Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoi...
Bellerophon Therapeutics (NASDAQ: BLPH ) stock is taking a massive beating on Monday after the pharmaceutical company posted poor clinical trial results. The bad news for BLPH stock comes from its Pha...
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH....
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad...
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad...
